FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
PTC Therapeutics receives refuse to file letter from FDA for its DMD drug Translarna; agency says NDA is 'not sufficiently complete' to permit substantive review.